RNA interference inhibits hepatitis E virus mRNA accumulation and protein synthesis in vitro

Veterinary Microbiology

Volumn 142, Issue 3-4, 2010, Pages 261-267

  Huang, Fen ^a   Zhou, Junfang ^a   Yang, Zhibiao ^a   Cui, Li ^a   Zhang, Wen ^a   Yuan, Congli ^a   Yang, Shixing ^a   Zhu, Jianguo ^a   Hua, Xiuguo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Hepatitis E virus; ORF2; RNAi

Indexed keywords

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEPATITIS E VIRUS; HUMAN; HUMAN CELL; INFECTION PREVENTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINANT PLASMID; RNA INTERFERENCE; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; VIRUS INHIBITION; WESTERN BLOTTING;

ANIMALS; CELL LINE; HEPATITIS E; HEPATITIS E VIRUS; PROTEIN BIOSYNTHESIS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA, VIRAL; SWINE; VIRAL PROTEINS;

HEPATITIS E VIRUS; MIRIDAE; RODENTIA; SUIDAE;

EID: 77952099288     PISSN: 03781135     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetmic.2009.10.023     Document Type: Article

References (42)

1. Abreu C. Viral hepatitis in travelers. Acta Med. Port. 2007, 20:557-566.
2. Aggarwal R., Krawczynshi K. Hepatitis E: an overview and recent advances in clinical and laboratory research. J. Gastroenterol. Hepatol. 2000, 15:9-20.
3. Akerstrom S., Mirazimi A., Tan Y.J. Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. Antivir. Res. 2007, 73:219-227.
4. Arankalle V.A., Joshi M.V., Kulkarni A.M., Gandhe S.S., Chobe L.P., Rautmare S.S., Mishra A.C., Padbidri V.S. Prevalence of anti-hepatitis E virus antibodies in different Indian animal species. J. Viral Hepat. 2001, 8:223-227.
5. Bouwknegt M., Lodder-Verschoor F., van der Poel W.H., Ruties S.A., De Roda Husan A.M. Hepatitis E virus RNA in commercial porcine livers in The Netherlands. J. Food Prot. 2007, 70:2889-2895.
6. Couzin J. Molecular biology. RNAi safety comes under security. Science 2006, 312:1121.
7. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
8. Feagins A.R., Opriessnig T., Guenette D.K., Halbur P.G., Meng X.J. Detection and characterization of infectious Hepatitis E virus from commercial pig liver sold in local grocery stores in the USA. J. Gen. Virol. 2007, 88:912-917.
9. Feagins A.R., Opriessnig T., Huang Y.W., Halbur P.G., Meng X.J. Cross-species infection of specific-pathogen-free pigs by a genotype 4 strain of human hepatitis E virus. J. Med. Virol. 2008, 80:1379-1386.
10. Gardner M.B., Luciw P.A. Macaque models of human infectious disease. ILAR J. 2008, 49:220-255.
11. Grimm D., Kay M.A. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?. J. Clin. Invest. 2007, 117:3633-3641.
12. Halbur P.G., Kasorndorkbua C., Gilbert C., Guenette D., Potters M.B., Purcell R.H., Emerson S.U., Toth T.E., Meng X.J. Comparative pathogenesis of infection of pigs with hepatitis E virus recovered from a pig and a human. J. Clin. Microbiol. 2001, 39:918-923.
13. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
14. He J., Tam A.W., Yarbough P.O., Reyes G.R., Carl R. Expression and diagnostic utility of hepatitis E virus putative structural protein expressed in insect cells. J. Clin. Microbiol. 1993, 31:2167-2173.
15. Hsieh S.Y., Meng X.J., Wu Y.H., Liu S.T., Tam A.W., Lin D.Y., Liaw Y.F. Identity of a novel swine hepatitis E virus in Taiwan forming a monophyletic group with Taiwan isolates of human hepatitis E virus. J. Clin. Microbiol. 1999, 37:3828-3834.
16. Huang R., Li D., Wei S., Li Q., Yuan X., Geng L., Li X., Liu M. Cell culture of sporadic hepatitis E virus in China. Clin. Diagn. Lab. Immunol. 1999, 6:729-733.
17. Kasorndorkbua C., Guenette D.K., Huang F.F., Thomas P.J., Meng X.J., Halbur P.G. Routes of transmission of swine hepatitis E virus in pigs. J. Clin. Microbiol. 2004, 42:5047-5052.
18. Kirchhoff F. Silencing HIV in vivo. Cell 2008, 134:566-568.
19. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., Albuquerque R.J., Yamasaki S., Itaya M., Pan Y., Appukuttan B., Gibbs D., Yang Z., Kariko K., Ambati B.K., Wilgus T.A., Dipietro L.A., Sakurai E., Zhang K., Smith J.R., Taylor E.W., Ambati J. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452:591-597.
20. Krawczynski K. Hepatitis E vaccine-ready for prime time?. N. Engl. J. Med. 2007, 356:949-951.
21. Kurreck J. siRNA efficiency: structure or sequence-that is the question. J. Biomed. Biotechnol. 2006, 2006:83757.
22. Ladunga I. More complete gene silencing by fewer siRNA: transparent optimized design and biophysical signature. Nucleic Acids Res. 2006, 35:433-440.
23. Lin J.T., Zhang J.S., Su N., Xu J.G., Wang N., Chen J.T., Chen X., Liu Y.X., Gao H., Jia Y.P., Liu Y., Sun R.H., Wang X., Yu D.Z., Hai R., Gao Q., Ning Y., Wang H.X., Li M.C., Kan B., Dong G.M., An Q., Wang Y.Q., Han J., Qin C., Yin W.D., Dongs X.P. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir. Ther. 2007, 12:1107-1113.
24. Li X., Kamili S., Krawczynski K. Quantitative detection of hepatitis E virus RNA and dynamics of viral replication in experimental infection. J. Viral Hepat. 2006, 13:835-839.
25. Liu M., Ding H., Zhao P., Qin Z.L., Gao J., Cao M.M., Luan J., Wu W.B., Qi Z.T. RNA interference effectively inhibits mRNA accumulation and protein expression of hepatitis C virus core and E2 genes in human cells. Biosci. Biotechnol. Biochem. 2006, 70:2049-2055.
26. Lorenzo F.R., Tanaka T., Takahashi H., Ichiyama K., Hoshino Y., Yamada K., Inoue J., Takahashi M., Okamoto H. Mutational events during the primary propagation and consecutive passages of hepatitis E virus strain JE03-1760F in cell culture. Virus Res. 2008, 137:86-96.
27. McBride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., Gilmore B.L., Burstein H., Peluso R.W., Polosky B., Carter B.J., Davidson B.L. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. USA 2008, 105:5868-5873.
28. Meng X.J., Wiseman B., Elvinger F., Guenette D.K., Toth T.E., Engle R.E., Emerson S.U., Purcell Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. J. Clin. Microbiol. 2002, 40:117-122.
29. Mungall B.A., Schopman N.C., Lambeth L.S., Doran T.J. Inhibition of Henipavirus infection by RNA interference. Antivir. Res. 2008, 80:324-331.
30. Mushahwar I.K. Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, epidemiology, and prevention. J. Med. Virol. 2008, 80:646-658.
31. Okamoto H., Takahashi M., Nishizawa T., Usui R., Kobayashi E. Presence of antibodies to hepatitis E virus in Japanese pet cats. Infection 2004, 32:57-58.
32. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
33. Riddell M.A., Li F., Anderson D.A. Identification of immunodominant and conformational epitopes in the capsid protein of hepatitis E virus by using monoclonal antibodies. J. Virol. 2000, 74:8011-8017.
34. Saif L.J. Animal coronavirus vaccines: lessons for SARS. Dev. Bio. (Base 1) 2004, 119:129-140.
35. Shao Y., Chan C.Y., Maliyekkel A., Lawrence C.E., Roninson I.B., Ding Y. Effect of target secondary structure on RNAi efficiency. RNA 2007, 13:1631-1640.
36. Shrestha M.P., Scott R.M., Joshi D.M., Mammen M.P., Thapa G.B., Thapa N., Myint K.S., Fourneau M., Kuschner R.A., Shrestha S.K., David M.P., Seriwatana J., Vaughn D.W., Safary A., Endy T.P., Innis B.L. Safety and efficacy of a recombinant hepatitis E vaccine. N. Engl. J. Med. 2007, 356:895-903.
37. Tacke F., Trautwein C. Efficient recombinant hepatitis E virus vaccine: mission accomplished?. Hepatology 2007, 46:941-943.
38. Tanaka T., Takahashi M., Kusano E., Okamoto H. Development and evaluation of an efficient cell-culture system for Hepatitis E virus. J. Gen. Virol. 2007, 88:903-911.
39. Tanaka T., Takahashi H., Ichiyama K., Hoshino Y., Yamada K., Inoue J., Takahashi M., Okamoto H. Mutational events during the primary propagation and consecutive passages of hepatitis E virus strain JE03-1760F in cell culture. Virus Res. 2008, 137:86-96.
40. Tei S., Kitajima N., Takahashi K., Mishiro S. Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 2003, 362:371-373.
41. Tsarev S.A., Tsareva T.S., Emerson S.U., Kapikian A.Z., Ticehurst J., London W., Purcell R.H. ELISA for antibody to hepatitis E virus (HEV) based on complete open-reading frame-2 protein expressed in insect cells: identification of HEV infection in primates. J. Infect. Dis. 1993, 168:369-378.
42. Vitral C.L., Pinto M.A., Lewis-Ximenez L.L., Khudyakov Y.E., dos Santos D.R., Gaspar A.M. Serological evidence of hepatitis E virus infection in different animal species from the Southeast of Brazil. Mem. Inst. Oswaldo Cruz 2005, 100:117-122.